Ruxolitinib for the treatment of inadequately controlled polycythemia vera without splenomegaly: 80-week follow-up from the RESPONSE-2 trial

to related objects

Location: Deutsche Nationalbibliothek Frankfurt am Main

ISSN: 1432-0584

Extent: Online-Ressource

Language: Englisch

Notes: online resource.

Bibliographic citation: Ruxolitinib for the treatment of inadequately controlled polycythemia vera without splenomegaly: 80-week follow-up from the RESPONSE-2 trial ; day:27 ; month:5 ; year:2018 ; pages:1-10
Annals of hematology ; (27.5.2018), 1-10

Creator: Griesshammer, Martin

Contributor: Saydam, Guray
Palandri, Francesca
Benevolo, Giulia
Egyed, Miklos
Callum, Jeannie
Devos, Timothy
Sivgin, Serdar
Guglielmelli, Paola
Bensasson, Caroline
Khan, Mahmudul
Ronco, Julian Perez
Passamonti, Francesco
SpringerLink (Online service)

DOI: 10.1007/s00277-018-3365-y

URN: urn:nbn:de:101:1-2018080309152093079831

Rights: Der Zugriff auf das Objekt ist unbeschränkt möglich.

Last update: 15.08.2025, 7:28 AM CEST

Data provider

This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.

Show original at data provider

Associated

Griesshammer, Martin
Saydam, Guray
Palandri, Francesca
Benevolo, Giulia
Egyed, Miklos
Callum, Jeannie
Devos, Timothy
Sivgin, Serdar
Guglielmelli, Paola
Bensasson, Caroline
Khan, Mahmudul
Ronco, Julian Perez
Passamonti, Francesco
SpringerLink (Online service)

Other Objects (12)

Ruxolitinib-treated polycythemia vera patients and their risk of secondary malignancies

Overcoming treatment challenges in myelofibrosis and polycythemia vera: the role of ruxolitinib

Ruxolitinib Adherence in Myelofibrosis and Polycythemia Vera: the “RAMP” Italian multicenter prospective study

Resolution of thrombocytopenia, but not polycythemia after ruxolitinib for polycythemia vera with detectable mutation in the exon 12 of the JAK2 gene

Hematocrit control and thrombotic risk in patients with polycythemia vera treated with ruxolitinib in clinical practice

Nothing Hurts Follow-Up like Follow-Up?

Ruxolitinib reduces JAK2 p.V617F allele burden in patients with polycythemia vera enrolled in the RESPONSE study

Incidence of solid tumors in polycythemia vera treated with phlebotomy with or without hydroxyurea: ECLAP follow-up data

$74-week follow-up of safety of infliximab in patients with refractory rheumatoid arthritis$

74-week follow-up of safety of infliximab in patients with refractory rheumatoid arthritis

Physical activity initiated by employer and its health effects; an eight week follow-up study

Hypersensitivity relief of MIH-affected molars using two sealing techniques: a 12-week follow-up

Serie

"Ardennes Follow-up Series"

Ruxolitinib-treated polycythemia vera patients and their risk of secondary malignancies

Overcoming treatment challenges in myelofibrosis and polycythemia vera: the role of ruxolitinib

Ruxolitinib Adherence in Myelofibrosis and Polycythemia Vera: the “RAMP” Italian multicenter prospective study

Resolution of thrombocytopenia, but not polycythemia after ruxolitinib for polycythemia vera with detectable mutation in the exon 12 of the JAK2 gene

Hematocrit control and thrombotic risk in patients with polycythemia vera treated with ruxolitinib in clinical practice

Nothing Hurts Follow-Up like Follow-Up?

Ruxolitinib reduces JAK2 p.V617F allele burden in patients with polycythemia vera enrolled in the RESPONSE study

Incidence of solid tumors in polycythemia vera treated with phlebotomy with or without hydroxyurea: ECLAP follow-up data

$74-week follow-up of safety of infliximab in patients with refractory rheumatoid arthritis$

74-week follow-up of safety of infliximab in patients with refractory rheumatoid arthritis

Physical activity initiated by employer and its health effects; an eight week follow-up study

Hypersensitivity relief of MIH-affected molars using two sealing techniques: a 12-week follow-up

Serie

"Ardennes Follow-up Series"

Ruxolitinib-treated polycythemia vera patients and their risk of secondary malignancies

Overcoming treatment challenges in myelofibrosis and polycythemia vera: the role of ruxolitinib

Ruxolitinib Adherence in Myelofibrosis and Polycythemia Vera: the “RAMP” Italian multicenter prospective study

Resolution of thrombocytopenia, but not polycythemia after ruxolitinib for polycythemia vera with detectable mutation in the exon 12 of the JAK2 gene

Hematocrit control and thrombotic risk in patients with polycythemia vera treated with ruxolitinib in clinical practice

Nothing Hurts Follow-Up like Follow-Up?

Ruxolitinib reduces JAK2 p.V617F allele burden in patients with polycythemia vera enrolled in the RESPONSE study

Incidence of solid tumors in polycythemia vera treated with phlebotomy with or without hydroxyurea: ECLAP follow-up data

$74-week follow-up of safety of infliximab in patients with refractory rheumatoid arthritis$

74-week follow-up of safety of infliximab in patients with refractory rheumatoid arthritis

Physical activity initiated by employer and its health effects; an eight week follow-up study

Hypersensitivity relief of MIH-affected molars using two sealing techniques: a 12-week follow-up

Serie

"Ardennes Follow-up Series"

Cultural heritage institutions wishing to register will find more information here.

Fields marked * need to be filled in.

Username*

Please enter your username

Email*

Please enter your email address

Please do not fill this field

First name

Last name

Password*

Please enter your password

Confirm password*

Please enter the same password

I have read the terms of use and the privacy policy for the collection of personal data and accept them. *

This field is required.

I would like to subscribe to the newsletter of the Deutsche Digitale Bibliothek. See newsletter subscription info.

Account created

Your "My DDB" account has been successfully created. Before you can log in to your account, you must click the confirmation link in the message we just sent to the email address you provided.

Ruxolitinib for the treatment of inadequately controlled polycythemia vera without splenomegaly: 80-week follow-up from the RESPONSE-2 trial

Object Details

References and Relationships

Contributors, Places and Time

Further information

Data provider

Associated

Other Objects (12)

Ruxolitinib-treated polycythemia vera patients and their risk of secondary malignancies

Overcoming treatment challenges in myelofibrosis and polycythemia vera: the role of ruxolitinib

Ruxolitinib Adherence in Myelofibrosis and Polycythemia Vera: the “RAMP” Italian multicenter prospective study

Resolution of thrombocytopenia, but not polycythemia after ruxolitinib for polycythemia vera with detectable mutation in the exon 12 of the JAK2 gene

Hematocrit control and thrombotic risk in patients with polycythemia vera treated with ruxolitinib in clinical practice

Nothing Hurts Follow-Up like Follow-Up?

Ruxolitinib reduces JAK2 p.V617F allele burden in patients with polycythemia vera enrolled in the RESPONSE study

Incidence of solid tumors in polycythemia vera treated with phlebotomy with or without hydroxyurea: ECLAP follow-up data

74-week follow-up of safety of infliximab in patients with refractory rheumatoid arthritis

Physical activity initiated by employer and its health effects; an eight week follow-up study

Hypersensitivity relief of MIH-affected molars using two sealing techniques: a 12-week follow-up

"Ardennes Follow-up Series"

Ruxolitinib-treated polycythemia vera patients and their risk of secondary malignancies

Overcoming treatment challenges in myelofibrosis and polycythemia vera: the role of ruxolitinib

Ruxolitinib Adherence in Myelofibrosis and Polycythemia Vera: the “RAMP” Italian multicenter prospective study

Resolution of thrombocytopenia, but not polycythemia after ruxolitinib for polycythemia vera with detectable mutation in the exon 12 of the JAK2 gene

Hematocrit control and thrombotic risk in patients with polycythemia vera treated with ruxolitinib in clinical practice

Nothing Hurts Follow-Up like Follow-Up?

Ruxolitinib reduces JAK2 p.V617F allele burden in patients with polycythemia vera enrolled in the RESPONSE study

Incidence of solid tumors in polycythemia vera treated with phlebotomy with or without hydroxyurea: ECLAP follow-up data

74-week follow-up of safety of infliximab in patients with refractory rheumatoid arthritis

Physical activity initiated by employer and its health effects; an eight week follow-up study

Hypersensitivity relief of MIH-affected molars using two sealing techniques: a 12-week follow-up

"Ardennes Follow-up Series"

Ruxolitinib-treated polycythemia vera patients and their risk of secondary malignancies

Overcoming treatment challenges in myelofibrosis and polycythemia vera: the role of ruxolitinib

Ruxolitinib Adherence in Myelofibrosis and Polycythemia Vera: the “RAMP” Italian multicenter prospective study

Resolution of thrombocytopenia, but not polycythemia after ruxolitinib for polycythemia vera with detectable mutation in the exon 12 of the JAK2 gene

Hematocrit control and thrombotic risk in patients with polycythemia vera treated with ruxolitinib in clinical practice

Nothing Hurts Follow-Up like Follow-Up?

Ruxolitinib reduces JAK2 p.V617F allele burden in patients with polycythemia vera enrolled in the RESPONSE study

Incidence of solid tumors in polycythemia vera treated with phlebotomy with or without hydroxyurea: ECLAP follow-up data

74-week follow-up of safety of infliximab in patients with refractory rheumatoid arthritis

Physical activity initiated by employer and its health effects; an eight week follow-up study

Hypersensitivity relief of MIH-affected molars using two sealing techniques: a 12-week follow-up

"Ardennes Follow-up Series"

Related objects

Reset password